TerminatedNCT01566630Updated Nov 5, 2015Results posted

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

A Phase 2 interventional study of Placebo and RLX030 in Pre-eclampsia, sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in 2 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2015-11-05.

Sponsored by Novartis Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated

Novartis terminated this study due to internal, strategic decisions.

Phase: Phase 2
Study type: Interventional
Enrollment: 3
Allocation: Randomized
Ages: 18 Years to 40 Years
Sex: Female

Study summary

This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can prolong pregnancy in women with pre-eclampsia.

Conditions studied

Pre-eclampsia

Browse trials for

Keywords

human recombinant RLX030
Pre-eclampsia
hemodynamics
Pharmacokinetics

In context

Eclampsia

328 studies on the registry are indexed under Eclampsia; 48 are open to participants now.

This study's enrollment of 3 is below the median of 120 across 169 interventional studies indexed under Eclampsia.

Browse Eclampsia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.

Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 40 Years
Sexes eligible: Female
Accepts healthy volunteers: No

Eligibility criteria

Key Inclusion criteria:

Written informed consent was obtained before any assessment was performed.
Women at 18 to 40 years of age with a pregnancy 28 weeks (0 days) and 33 weeks (+4 days) gestational age. Gestational age was based on mother's last menstruation; if last menstruation was unknown, an alternative method was used as applicable and was documented in the (electronic) Case Report/Record Form [(e)CRF].
Women with a diagnosis of pre-eclampsia or superimposed pre-eclampsia requiring hospitalization. Pre-eclampsia was defined as new onset of hypertension (SBP ≥ 140 or DBP ≥ 90 mmHg) or gestational hypertension accompanied by proteinuria (>= 0.3 g/24h) after 20 weeks of gestation. Superimposed pre-eclampsia was defined as chronic hypertension with new onset of proteinuria after 20 weeks of gestation.
Reassuring fetal testing (cardiotocography and biophysical profile)

Key Exclusion criteria:

Severe hypertension (SBP ≥ 160 mmHg or DBP ≥ 110 mmHg) and /or those receiving anti-hypertensive treatment at time of randomization.
Clinically relevant electrocardiogram (ECG) abnormalities at screening excluding those abnormalities commonly seen in pregnancy according to the Investigator.
Symptoms indicative of severe pre-eclampsia or HELLP syndrome (Hemolysis, Elevated Liver enzymes, and Low Platelet count) for which immediate delivery of the baby may be indicated. Symptoms include persistent CNS symptoms (severe headaches, visual changes, altered mentation), persistent right upper quadrant or epigastric pain, nausea or vomiting, severe thrombocytopenia (\<100,000/mm3) and abnormal (> 2X upper limit of normal) liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]).
Eclampsia during current pregnancy, vaginal bleeding present at screening, abruptio placentae, oligohydramnios
Current diagnosis of a seizure disorder that requires chronic medication.
Pre-gestational diabetes (Type 1 or Type 2) with or without diabetic retinopathy. Diagnosis (previous or current) of gestational diabetes, regardless of treatment, was allowed
Known allergy to magnesium sulfate or steroids.
Multifetal gestation, known major fetal anomaly, intrauterine growth restriction (\<5th percentile).

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Investigator)
Enrollment: 3 participants (actual)

Study arms

Experimental
RLX030
In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030. In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1.
Drug: RLX030
Placebo comparator
Placebo
In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts. In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours
Drug: Placebo

Interventions

DrugPlacebo
Placebo to RLX030 as intravenous infusion for 72 hours
DrugRLX030
RLX030 1 mg/mL vials

What researchers measure

Primary outcomes

Number of Patients With Adverse Events, Serious Adverse and Death During Part 1 of the Study
Safety and tolerability was assessed by adverse events/serious adverse event and death monitoring.
Time frame: Prior to delivery until 4-6 weeks post partum (maximum of 8 weeks)
Change From Baseline in Maternal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Part 1of the Study (Part 1)
Maternal safety assessment to monitor pre-eclampsia by checking blood pressure during 72 hour treatment period as well as post-dose.
Time frame: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)
Change From Baseline in Mean Maternal Arterial Pressure (Part 1)
Maternal safety assessment to monitor pre-eclampsia by checking mean arterial pressure during 72 hour treatment period as well as post-dose.
Time frame: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)
Change From Baseline on Maternal Proteinuria (Part 1)
Pre-eclampsia was monitored by checking levels of protein in urine and by urinary protein/creatinine ratio (UPCR)
Time frame: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)
Decrease in Utero-placental Blood Flow (Part 1)
Blood flow to the fetus was monitored using via a Doppler.
Time frame: During treatment period of a maximum 72 hours infusion prior to delivery and up to delivery in part 1 (maximum of 3 weeks)
Change in Fetal Heart Rate (Part 1)
Heart rate of fetus was monitored continuously throughout 72 hour treatment period using a cardiotocograph.
Time frame: During treatment period of a maximum 72 hours infusion prior to delivery and up to delivery in part 1 (maximum of 3 weeks)
Improvement in Renal Function Assessed by Increase in Creatinine Clearance
Time frame: From randomization until 4-6 weeks post partum (maximum 8 weeks)
Rate of Spontaneous Delivery and/or Mode of Delivery
Time frame: From randomization to delivery (maximum of 3 weeks)
Number of Patients With Absence of Anti-serelaxin Antibodies
Time frame: From Randomization until 4-6 weeks post partum (maximum of 8 weeks)
Number of Patients With Abnormalities in Birth Weight, Gestational Age, Appearance, Pulse, Grimace, Activity, Respiration (APGAR) Score, Umbilical Cord Gases, and Days in Neonatal Intensive Care Unit (NICU)
Time frame: up to 4 - 6 weeks post partum (maximum of 8 weeks )
Number of Patients With Abnormalities in Fetal Cardiotocography and Biophysical Profile
Time frame: Randomization to delivery (maximum of 3 weeks)
Pharmacokinetics of RLX030: Area Under the Blood Concentration-time Curve From Time Zero to Infinity (AUCinf)-Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Area Under the Blood Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)-Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Blood Concentration at 24 Hour (C 0-24h) After Administration- Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Terminal Elimination Half-life (T1/2)- Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Mean Residence Time (MRT)
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1

Secondary outcomes

Mean Number of Days Before Delivery
Time frame: From randomization until delivery (maximum of 3 weeks)

Results

Posted Nov 5, 2015

Participant flow

Participant flow — Overall Study
Milestone	RLX030	Placebo
Started	2	1
Completed	2	1
Not completed	0	0

Outcome measures

PrimaryNumber of Patients With Adverse Events, Serious Adverse and Death During Part 1 of the Study

Safety and tolerability was assessed by adverse events/serious adverse event and death monitoring.

Time frame:: Prior to delivery until 4-6 weeks post partum (maximum of 8 weeks)
Reported as:: Number · Participants

Number of Patients With Adverse Events, Serious Adverse and Death During Part 1 of the Study
Participants	RLX030 - Maternal	Placebo - Maternal	RLX030- Neonates Born to Patients	Placebo- Neonates Born to Patients
Serious Adverse events	2	1	2	1
Death	0	0	0	0
Non-serious AEs	2	1	2	0

PrimaryChange From Baseline in Maternal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Part 1of the Study (Part 1)

Maternal safety assessment to monitor pre-eclampsia by checking blood pressure during 72 hour treatment period as well as post-dose.

Time frame:: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)